Categories: Health

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 13, 2025 /PRNewswire/ — Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer’s disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation (β-amyloid clearance), and anti-inflammatory effects (through NF-κB inhibition) through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment.

- Advertisement -

The Phase I trial showed excellent safety, tolerability, and pharmacokinetics at 100–200 mg in both healthy and elderly adults. TML-6 will now advance to a Phase II 19 site trial across the United States, Sweden, and Taiwan after FDA approval. This 12-month study will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia.

- Advertisement -

Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO.

With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer’s disease.

- Advertisement -

About Merry Life Biomedical Company

- Advertisement -

Merry Life Biomedical is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs.

Media Contact
Dr. Ih-Jen Su
Merry Life Biomedical Company, Ltd.
Phone: +886-910-902-296
Email: suihjen0704@stust.edu.tw 

- Advertisement -

Logo – https://mma.prnewswire.com/media/2708243/Merry_Life_LOGO_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/merry-life-launches-global-phase-ii-trial-of-tml-6-the-first-drug-targeted-at-autolysosome-pathway-for-therapy-of-alzheimers-disease-302478755.html

PRNW Agency

Recent Posts

LG’s Radio Optimism Campaign Inspires People to Share Their Love with Family and Loved Ones Through One-of-a-Kind AI Songs

SEOUL, South Korea, Sept. 25, 2025 /PRNewswire/ -- LG Electronics (LG) today announced the success…

7 minutes ago

Milliken Assure Moisture Barrier Wins 2025 R&D 100 Award

Diversified global manufacturer recognized for redefining moisture barrier performance in firefighter turnout gear SPARTANBURG, S.C.,…

7 minutes ago

Fynd Enters GCC to Power the Region’s Next Wave of Retail Innovation

Fynd opens its first international office in the GCC, establishing its Middle East presence and…

2 hours ago

Signature Global Strengthens Connection with NRIs in USA’s Rhode Island through Investor Engagement Programme

Signature Global, one of India's leading real estate developers, has strengthened its engagement with Non-Resident…

2 hours ago

Phemex Revamps Blog to Deliver Deeper Insights and Enhanced Reader Experience

APIA, Samoa, Sept. 25, 2025 /PRNewswire/ -- Phemex, the most efficient crypto exchange, has launched a…

2 hours ago

NAR India Appoints UCO as Exclusive MLS Implementer to Transform Indian Real Estate and Unlock Global Opportunities

Agreement paves the way for an empowered real estate ecosystem across India ALTAMONTE SPRINGS, Fla.,…

2 hours ago